This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

Progenics Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

TARRYTOWN, N.Y., June 20, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today the pricing of an underwritten public offering of 8,500,000 primary shares of its common stock at a public offering price of $4.40 per share. The gross proceeds from the sale of the shares, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $37,400,000. The offering is expected to close on or about June 25, 2013, subject to customary closing conditions. Progenics also granted the underwriters a 30-day option to purchase 1,275,000 additional shares of common stock. All of the shares sold in the offering are being sold by Progenics, with the proceeds to be used for research and development and general corporate purposes.

Jefferies LLC is acting as sole book-running manager for the offering. Needham & Company, LLC, Stifel and Brean Capital, LLC are acting as co-managers for the offering.

A shelf registration statement relating to the shares of common stock described above has been filed with and declared effective by the U.S. Securities and Exchange Commission. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any offer, if at all, will be made only by means of a prospectus, including a final prospectus supplement, forming part of the effective shelf registration statement.

A preliminary prospectus supplement relating to the offering has been filed with the SEC on June 19, 2013, and a final prospectus supplement relating to the offering will be filed with the SEC and will be available on its web site at
www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus, when available, may be obtained from Jefferies LLC., Equity Syndicate Prospectus Department, at 520 Madison Avenue, New York, New York, 10022, or by calling (877) 547-6340, or by emailing Prospectus_Department@Jefferies.com.

About Progenics

Progenics Pharmaceuticals, Inc. is discovering and developing innovative medicines for oncology, with a pipeline that includes product candidates in preclinical through late-stage development. Its first commercial product, Relistor
® (methylnaltrexone bromide) for opioid-induced constipation, is marketed and in further development by Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. is developing the subcutaneous formulation. For additional information, please visit
www.progenics.com.

This press release may contain projections and other forward-looking statements regarding future events. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, market and other conditions; the satisfaction of customary closing conditions related to the offering; the cost, timing, design, conduct and results of clinical trials and other development activities; market acceptance for approved products; generic and other competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; and possible safety or efficacy concerns, general business, financial and accounting matters, litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and periodic reports and filings with the U.S. Securities and Exchange Commission. Progenics is providing the information in this press release as of its date and does not undertake any obligation to update or revise it, whether as a result of new information, future events or circumstances or otherwise.

Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release.